^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Mobilan (M-VM3)

    i
    Other names: M-VM3, recombinant non-replicating adenovirus, MVAME03
    Associations

    News

    Trials
    Company:
    Statera BioPharma
    Drug class:
    TLR5 agonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    Flagellins as Vaccine Adjuvants and Cancer Immunotherapy: Recent Advances and Future Prospects. (PubMed, Immunology)
    Mobilan, a recombinant non-replicating adenovirus vector expressing Salmonella flagellin, is currently in a phase Ib clinical trial for prostate cancer. Overall, bacterial flagellin treatments are generally safe, well-tolerated, and associated with minimal side effects, making them a promising option for managing infectious diseases and cancers.
    Review • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL1B (Interleukin 1, beta)
    |
    Mobilan (M-VM3)
    over5years
    First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients. (PubMed, Oncotarget)
    Therefore, Mobilan is well-tolerated and induces the expected pharmacodynamic response in humans. These results support further clinical development of Mobilan as a novel immunotherapy for prostate cancer.
    Clinical • P1 data • PK/PD data • Journal
    |
    IL6 (Interleukin 6)
    |
    Mobilan (M-VM3)